Dr. Lowell Anthony: Use of Telotristat Etiprate in Patients With Carcinoid Syndrome
Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristat etiprate in patients with inadequately controlled carcinoid syndrome.
Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate etiprate in patients with inadequately controlled carcinoid syndrome. Anthony says oncologists now have a new option for patients with carcinoid syndrome, which no longer responds to somatostatin analogs.
The trial was a prospective, randomized, placebo-controlled trial enrolled more than 100 patients, one-third of which received placebos. Patients reported symptoms mainly consisting of diarrhea and the frequency of it, physical function, and impact these symptoms had on their quality of life. Of the 35 participants, 14 patients did not report any signs of improvement, 7 patients had somewhat improvement, and 12 had definite improvement. The reduction in diarrhea allowed for better quality of life, Anthony adds.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
